ProfileGDS5678 / 1455582_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 79% 77% 76% 76% 80% 76% 75% 78% 76% 77% 77% 76% 77% 77% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.4430379
GSM967853U87-EV human glioblastoma xenograft - Control 25.2446477
GSM967854U87-EV human glioblastoma xenograft - Control 35.1667876
GSM967855U87-EV human glioblastoma xenograft - Control 45.2047576
GSM967856U87-EV human glioblastoma xenograft - Control 55.7051980
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.9498176
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.9101675
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.381578
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.165476
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.2301277
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.242877
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.1754276
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.2284877
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.2215877